ERBB2 and neoplasm: Furthermore, this signature was now able to identify tumours with poor DMFS in nearly all subgroups analysed (ERpos, ERneg, LNpos, LNneg, ERpos/LNneg, Grade-2, -3, Luminal A, Luminal B, ErbB2, Basal, untreated and tamoxifen-treated) (Fig. 6C-E; Additional file 14: Figure S11) with the exception of Normal-like cancers (P = 0.10) and Grade-1 cancers (P = 0.10) (Fig. 6E; Additional file 14: Figure S11).